Effects of valproate on serum leptin, insulin, and lipid lev
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Weight gain is an important adverse effect of valproate (VPA) therapy. Number of mechanisms have been proposed for its pathophysiology. The aim of the present study is evaluation of biochemical derangements in epileptic children on treatment with VPA.

30 epileptic children treated with VPA and 20 age–sex-matched healthy children were enrolled in this study. Blood samples were received and body mass index were calculated from all of the subjects. Serum insulin, leptin and lipid levels have been compared between two groups.

--Leptin levels were significantly higher in patient group whereas BMI values were comparable.

-- There was a positive correlation between leptin and BMI among both patient and control groups (r=0.464, r=0.734 respectively).

-- Total cholesterol and LDL cholesterol levels were lower in VPA-treated epileptic children in comparison to control group (p=0.008; p=0.003 respectively).

-- No significant difference was determined in insulin levels between two groups.

-- A negative correlation was observed between plasma VPA level and TC and LDL-C levels in patients group (r = 0.380, r = 0.474 respectively).

In conclusion, despite identical BMI values, the analysis showed higher levels of leptin within the patient community. Thus, the VPA is likely to induce resistance to leptin. In contrast to other antiepileptics, serum cholesterol levels are not increased by VPA. In the VPA patients receiving this report, however, lower levels of total and low-density Lipoprotein (LDL) cholesterol were observed.

Source: https://onlinelibrary.wiley.com/doi/abs/10.1111/ped.14674?af=R